21:24 , May 11, 2017 |  BC Innovations  |  Translation in Brief

Going universal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell...
01:00 , Jun 20, 2015 |  BC Extra  |  Financial News

Celyad shares fall after U.S. listing

Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) dropped $13.99 (20%) to $54.57 in its first day of trading on NASDAQ Friday after it raised $100.1 million through the sale of ADSs and a private placement of ordinary shares....
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

CAR-NKG2D: Phase I started

Cardio3 began an open-label, U.S. Phase I trial to evaluate single doses of IV CAR-NKG2D in about 24 patients with acute myelogenous leukemia (AML) or multiple myeloma (MM). Patients will receive doses comprising 1x10 6,...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

C-Cure: Phase III ongoing

An independent DSMB recommended continuation of the double-blind, sham-controlled, European and Israeli Phase III CHART-1 trial evaluating a catheter injection of C-Cure based on a review of safety and efficacy data after all 240 advanced...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Financial News

Cardio3 BioSciences proposes follow-on

Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium   Business: Cardiovascular   Date announced: 2015-04-01   Type: Follow-on   To be raised: TBD   Shares: TBD   Price prior: EUR43.95   Note: Cardio3 proposed a public offering...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Financial News

Cardio3 BioSciences S.A completes private placement

Cardio3 BioSciences S.A . (Euronext:CARD), Mont-Saint-Guibert, Belgium   Business: Cardiovascular   Date completed: 2015-02-27   Type: Private placement   Raised: EUR31.8 million ($36 million)   Shares: 713,380   Price: EUR44.50   Shares after offering: 7.8...
02:37 , Feb 28, 2015 |  BC Extra  |  Financial News

Cardio3 raises EUR 31.7M

Cardio3 BioSciences S.A. (Euronext:CARD) raised EUR 31.7 million ($36 million) through the sale of 713,380 shares at EUR 44.50 in a private placement with undisclosed institutional investors in the U.S. and Europe. UBS was the...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

C-Cure: Completed Phase III enrollment

Cardio3 completed enrollment in the double-blind, sham-controlled, European and Israeli Phase III CHART-1 trial evaluating a catheter injection of C-Cure in =240 advanced CHF patients. Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium   Product: C-Cure (...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

C-Cure: Phase III start

By year end, Cardio3 will begin the double-blind, sham-controlled, international Phase III CHART-2 trial to evaluate C-Cure comprising 600 million cells in =240 patients. Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium   Product: C-Cure ( C3BS-CQR-1...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

CorQuest Medical, Cardio3 BioSciences deal

Cardio3 acquired cardiovascular device company CorQuest for an undisclosed amount. Cardio3 plans to launch its acquired heart access technology to repair or replace the mitral valve in Europe by year end 2016. Cardio3 declined to...